Updates are available Correction dated 2025-10-23
Click to view Correction: https://doi.org/10.1038/s41575-025-01145-w
-
Authors
Taylor, Sarah A.
Bader, Gary D. https://orcid.org/0000-0003-0185-8861
MacParland, Sonya
Mullen, Alan C. https://orcid.org/0000-0002-4096-3106
Andrews, Tallulah https://orcid.org/0000-0003-1120-2196
Cuenca, Alex G.
DasGupta, Ramanuj https://orcid.org/0000-0001-9015-3729
Gehring, Adam J.
Grün, Dominic https://orcid.org/0000-0002-3364-5898
Guilliams, Martin
Gulamhusein, Aliya
Henderson, Neil C. https://orcid.org/0000-0002-2273-4094
Hirschfield, Gideon
Huppert, Stacey S. https://orcid.org/0000-0003-3977-8728
Itzkovitz, Shalev https://orcid.org/0000-0003-0685-2522
Jiang, Z. Gordon
Lauer, Georg M. https://orcid.org/0000-0002-9792-4271
McGilvray, Ian
Mysore, Krupa R. https://orcid.org/0000-0001-9890-5518
Pirola, Carlos J. https://orcid.org/0000-0001-8234-4058
Quon, Gerald
Rahbari, Mohammad https://orcid.org/0000-0003-1133-2134
Regev, Aviv
Ricciuto, Amanda
Scott, Charlotte L.
Sharma, Ankur
Sookoian, Silvia https://orcid.org/0000-0001-5929-5470
Tana, Michele M. https://orcid.org/0000-0002-3665-2735
Teichmann, Sarah A.
Vallier, Ludovic https://orcid.org/0000-0002-3848-2602
Vlachos, Ioannis S.
Wang, Bruce
Zhen, Mei
- License Information
-
More Information
Article History
Accepted: 11 August 2025
First Online: 13 October 2025
Change Date: 23 October 2025
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41575-025-01145-w
Competing interests
: S. A. Taylor serves as a consultant for Ipsen Pharmaceutical. A.C.M. receives funding from GSK and Boehringer Ingelheim for unrelated projects. A.J.G. receives research funding from Aligos Therapeutics, Bluejay Therapeutics, GSK, Roche and Vir Biotechnology, and performs scientific advisory services for Aligos Therapeutics, Arbutus Biopharma, Assembly Biosciences, Bluejay Therapeutics, Gilead Sciences, GSK, Janssen Pharmaceuticals, Roche, Vir Biotechnology, Virion Therapeutics and VBI for unrelated projects. D.G. serves as a consultant for Gordian Biotechnology. M.G. receives funding from the Sanofi iTech Award programme for an unrelated project. N.C.H. has received research funding from AbbVie, Pfizer, Gilead and Boehringer-Ingelheim, and is an adviser or consultant for Astra-Zeneca, GSK and MSD. S.S.H serves as a consultant for ARNATAR Therapeutics. Z.G.J. serves on the advisory board of Olix Pharmaceuticals, and received grants from Pfizer and Gilead Sciences. A. Ricciuto receives a stipend for academic lectures from Janssen and Organon. C.L.S. receives funding from Novo Nordisk for unrelated projects. M.M.T has served as a consultant for Merck for an unrelated project. L.V. is a shareholder of Definigen, BiliTech and Bit.bio. I.S.V. consults for Guidepoint Global, Cowen and Mosaic. B.W. serves as a consultant for Alnylam Pharmaceuticals, Disc Medicine, Mitsubishi Tanabe Pharma and Recordati Rare Diseases. G.D.B. advises Adela Bio and BioRender. The other authors declare no competing interests.
